APA (7th ed.) Citation

SAMYSHKIN, Y., Purser, M., Dlotko, E., Macleod, P., Breslin, K., Boytsov, N., . . . Suvannasankha, A. (2025). SA25 Burden of Administration: Belantamab Mafodotin (Belamaf) Combinations vs Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d), Daratumumab (D) + K + d, and K + d in Relapsed/Refractory Multiple Myeloma (RRMM). Value in Health, 28(6), S399. https://doi.org/10.1016/j.jval.2025.04.1780

Chicago Style (17th ed.) Citation

SAMYSHKIN, Yevgeniy, Molly Purser, Ewa Dlotko, Paul Macleod, Katie Breslin, Natalie Boytsov, Simon McNamara, Sandhya Sapra, and Attaya Suvannasankha. "SA25 Burden of Administration: Belantamab Mafodotin (Belamaf) Combinations Vs Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d), Daratumumab (D) + K + D, and K + D in Relapsed/Refractory Multiple Myeloma (RRMM)." Value in Health 28, no. 6 (2025): S399. https://doi.org/10.1016/j.jval.2025.04.1780.

MLA (9th ed.) Citation

SAMYSHKIN, Yevgeniy, et al. "SA25 Burden of Administration: Belantamab Mafodotin (Belamaf) Combinations Vs Isatuximab (Isa) + Carfilzomib (K) + Dexamethasone (d), Daratumumab (D) + K + D, and K + D in Relapsed/Refractory Multiple Myeloma (RRMM)." Value in Health, vol. 28, no. 6, 2025, p. S399, https://doi.org/10.1016/j.jval.2025.04.1780.